ArriVent BioPharma, Inc. Quarterly Retained Earnings (Accumulated Deficit) in USD from Q4 2023 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
ArriVent BioPharma, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q4 2023 to Q2 2024.
  • ArriVent BioPharma, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending June 30, 2024 was -$197M.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 -$197M Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$175M Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$158M Dec 31, 2023 10-Q 2024-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.